Ticker
AGEN

Price
2.89
Stock movement down
-0.10 (-3.34%)
Company name
Agenus Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
817.46M
Ent value
983.41M
Price/Sales
2.64
Price/Book
52.01
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-52.47%
3 year return
0.82%
5 year return
-4.25%
10 year return
-4.64%
Last updated: 2022-08-25

DIVIDENDS

AGEN does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF1641.49
Price to FCF-
Price to EBITDA12.58
EV to EBITDA15.13

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.64
Price to Book52.01
EV to Sales3.17

FINANCIALS

Per share

Loading...
Per share data
Current share count282.86M
EPS (TTM)-0.09
FCF per share (TTM)-0.22

Income statement

Loading...
Income statement data
Revenue (TTM)309.89M
Gross profit (TTM)69.78M
Operating income (TTM)67.17M
Net income (TTM)-23.43M
EPS (TTM)-0.09
EPS (1y forward)-0.64

Margins

Loading...
Margins data
Gross margin (TTM)22.52%
Operating margin (TTM)21.68%
Profit margin (TTM)-7.56%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash247.71M
Net receivables1.29M
Total current assets290.48M
Goodwill24.62M
Intangible assets7.75M
Property, plant and equipment0.00
Total assets441.31M
Accounts payable34.54M
Short/Current long term debt64.31M
Total current liabilities163.06M
Total liabilities413.65M
Shareholder's equity15.72M
Net tangible assets231.36M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)498.00K
Capital expenditures (TTM)55.16M
Free cash flow (TTM)-54.67M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-149.03%
Return on Assets-5.31%
Return on Invested Capital-149.03%
Cash Return on Invested Capital-347.79%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.03
Daily high3.04
Daily low2.87
Daily Volume2.37M
All-time high315.75
1y analyst estimate9.67
Beta1.08
EPS (TTM)-0.09
Dividend per share-
Ex-div date-
Next earnings date7 Nov 2022

Downside potential

Loading...
Downside potential data
AGENS&P500
Current price drop from All-time high-99.08%-12.18%
Highest price drop-99.59%-56.47%
Date of highest drop14 Jun 20229 Mar 2009
Avg drop from high-92.62%-11.38%
Avg time to new high1892 days12 days
Max time to new high5653 days1805 days
COMPANY DETAILS
AGEN (Agenus Inc) company logo
Marketcap
817.46M
Marketcap category
Small-cap
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Employees
441
SEC filings
CEO
Garo H. Armen
Country
USA
City
Lexington
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found